NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
38 hedge funds and large institutions have $2.52M invested in NeuBase Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 8 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
5% less funds holding
Funds holding: 40 → 38 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
35% less capital invested
Capital invested by funds: $3.85M → $2.52M (-$1.33M)
63% less call options, than puts
Call options by funds: $3K | Put options by funds: $8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$237K |
| 2 |
CC
Cannell & Co
New York
|
+$197K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$42.2K |
| 4 |
Goldman Sachs
New York
|
+$40.8K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$31.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$556K |
| 2 |
B
Bailard
Foster City,
California
|
-$373K |
| 3 |
BlackRock
New York
|
-$70.9K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$34K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$34K |
NBSE Hedge Fund Activity: Q2 2017 in Review
38 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2017, worth a combined $2.52M — down 35% from $3.85M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of NBSE and 6 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $237K. The largest seller was Sabby Management, cutting an estimated $556K.
- 38 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2017, down from 40 in Q1 2017.
- Funds reported $2.52M of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2017, down 35% quarter-over-quarter.
- 6 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2017 and 8 closed out, a net change of -2 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2017 was Renaissance Technologies, an estimated $237K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2017 was Sabby Management, an estimated $556K sold.
Based on aggregated 13F filings for Q2 2017.